Clinical trials
Phase 2 Skin Diseases trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
63 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2006 | 2 |
| 2008 | 1 |
| 2010 | 1 |
| 2011 | 3 |
| 2012 | 1 |
| 2013 | 2 |
| 2015 | 1 |
| 2016 | 4 |
| 2017 | 4 |
| 2018 | 4 |
| 2019 | 3 |
| 2020 | 4 |
| 2021 | 5 |
| 2022 | 10 |
| 2023 | 3 |
| 2024 | 3 |
| 2025 | 6 |
| 2026 | 4 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 42 |
| Recruiting | 6 |
| Terminated | 6 |
| Active, not recruiting | 4 |
| Not yet recruiting | 1 |
| Suspended | 1 |
| Enrolling by invitation | 1 |
| Unknown status | 1 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Incyte Corporation | 5 |
| Akros Pharma Inc. | 2 |
| Amgen | 2 |
| Apollo Therapeutics Ltd | 2 |
| Caliway Biopharmaceuticals Co., Ltd. | 2 |
| Dermata Therapeutics | 2 |
| Forte Biosciences, Inc. | 2 |
| Inmagene LLC | 2 |
| MoonLake Immunotherapeutics AG | 2 |
| Novartis Pharmaceuticals | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Skin Diseases | 63 |
| Dermatitis | 13 |
| Dermatitis, Atopic | 13 |
| Eczema | 13 |
| Psoriasis | 12 |
| Immune System Diseases | 9 |
| Hidradenitis Suppurativa | 7 |
| Autoimmune Diseases | 6 |
| Connective Tissue Diseases | 5 |
| Skin Ulcer | 5 |
Trials
Showing 1 to 25 of 63. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.